Literature DB >> 12045735

Immunopathogenesis of acute transverse myelitis.

Douglas A Kerr1, Harold Ayetey.   

Abstract

Acute transverse myelitis is a group of disorders characterized by focal inflammation of the spinal cord and resultant neural injury. Acute transverse myelitis may be an isolated entity or may occur in the context of multifocal or even multisystemic disease. It is clear that the pathological substrate--injury and dysfunction of neural cells within the spinal cord--may be caused by a variety of immunological mechanisms. For example, in acute transverse myelitis associated with systemic disease (i.e. systemic lupus erythematosus or sarcoidosis), a vasculitic or granulomatous process can often be identified. In idiopathic acute transverse myelitis, there is an intraparenchymal or perivascular cellular influx into the spinal cord, resulting in the breakdown of the blood-brain barrier and variable demyelination and neuronal injury. There are several critical questions that must be answered before we truly understand acute transverse myelitis: (1) What are the various triggers for the inflammatory process that induces neural injury in the spinal cord? (2) What are the cellular and humoral factors that induce this neural injury? and (3) Is there a way to modulate the inflammatory response in order to improve patient outcome? Although much remains to be elucidated about the causes of acute transverse myelitis, tantalizing clues as to the potential immunopathogenic mechanisms in acute transverse myelitis and related inflammatory disorders of the spinal cord have recently emerged. It is the purpose of this review to illustrate recent discoveries that shed light on this topic, relying when necessary on data from related diseases such as acute disseminated encephalomyelitis, Guillain-Barré syndrome and neuromyelitis optica. Developing a further understanding of how the immune system induces neural injury will depend upon confirmation and extension of these findings and will require multicenter collaborative efforts.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12045735     DOI: 10.1097/00019052-200206000-00019

Source DB:  PubMed          Journal:  Curr Opin Neurol        ISSN: 1350-7540            Impact factor:   5.710


  23 in total

Review 1.  Immune mediated diseases and immune modulation in the neurocritical care unit.

Authors:  Gloria von Geldern; Thomas McPharlin; Kyra Becker
Journal:  Neurotherapeutics       Date:  2012-01       Impact factor: 7.620

2.  Intrathecal immunoglobulin production in patients with systemic lupus erythematosus with neuropsychiatric manifestations.

Authors:  Mo Yin Mok; Eric Y T Chan; Woon Sing Wong; Chak Sing Lau
Journal:  Ann Rheum Dis       Date:  2007-06       Impact factor: 19.103

3.  Human glial-restricted progenitors survive, proliferate, and preserve electrophysiological function in rats with focal inflammatory spinal cord demyelination.

Authors:  Piotr Walczak; Angelo H All; Nidhi Rumpal; Michael Gorelik; Heechul Kim; Anil Maybhate; Gracee Agrawal; James T Campanelli; Assaf A Gilad; Douglas A Kerr; Jeff W M Bulte
Journal:  Glia       Date:  2010-12-29       Impact factor: 7.452

Review 4.  The emergency room in systemic rheumatic diseases.

Authors:  G Slobodin; A Hussein; M Rozenbaum; I Rosner
Journal:  Emerg Med J       Date:  2006-09       Impact factor: 2.740

5.  The clinical course of idiopathic acute transverse myelitis in patients from Rio de Janeiro.

Authors:  Marina Papais Alvarenga; Luiz Claudio Santos Thuler; Silvio Peçanha Neto; Claudia Cristina Ferreira Vasconcelos; Solange Gomes Camargo; Marcos Papais Alvarenga; Regina Maria Papais-Alvarenga
Journal:  J Neurol       Date:  2010-02-03       Impact factor: 4.849

6.  Recurrent transverse myelitis following neurobrucellosis: immunologic features and beneficial response to immunosuppression.

Authors:  Chitra Krishnan; Adam I Kaplin; Jerome S Graber; Jessica S Darman; Douglas A Kerr
Journal:  J Neurovirol       Date:  2005-04       Impact factor: 2.643

7.  Expansion of CD27high plasmablasts in transverse myelitis patients that utilize VH4 and JH6 genes and undergo extensive somatic hypermutation.

Authors:  A J Ligocki; W H Rounds; E M Cameron; C T Harp; E M Frohman; A M Courtney; S Vernino; L G Cowell; B Greenberg; N L Monson
Journal:  Genes Immun       Date:  2013-04-18       Impact factor: 2.676

8.  Acute transverse myelitis at the conus medullaris level after rabies vaccination in a patient with Behçet's disease.

Authors:  Levent Sinan Bir; Fatma Ozdemir Eşmeli; Utku Cenikli; Cağdaş Erdoğan; Eylem Değirmenci
Journal:  J Spinal Cord Med       Date:  2007       Impact factor: 1.985

Review 9.  Pain and spinal cord imaging measures in children with demyelinating disease.

Authors:  Nadia Barakat; Mark P Gorman; Leslie Benson; Lino Becerra; David Borsook
Journal:  Neuroimage Clin       Date:  2015-09-06       Impact factor: 4.881

10.  Acute Transverse Myelitis (ATM):Clinical Review of 43 Patients With COVID-19-Associated ATM and 3 Post-Vaccination ATM Serious Adverse Events With the ChAdOx1 nCoV-19 Vaccine (AZD1222).

Authors:  Gustavo C Román; Fernando Gracia; Antonio Torres; Alexis Palacios; Karla Gracia; Diógenes Harris
Journal:  Front Immunol       Date:  2021-04-26       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.